Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sashas Blend is a veterinary nutraceutical developed by Interpath Global, specifically formulated to support canine joint health and mobility. It is composed of a proprietary blend of marine concentrates, including Green Lipped Mussel (Perna canaliculus), Abalone (Haliotis iris), and Shark Cartilage. These ingredients provide a rich source of glycosaminoglycans (GAGs) such as chondroitin sulfate, as well as omega-3 fatty acids (including eicosatetraenoic acids) and essential minerals. The supplement works by providing the structural building blocks for cartilage repair, inhibiting inflammatory mediators like prostaglandins and leukotrienes through the modulation of cyclooxygenase and lipoxygenase pathways, and improving synovial fluid viscosity. It is primarily used to manage symptoms of osteoarthritis and degenerative joint disease in dogs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sashas Blend.